Navigation Links
Pharma IQ's Drug Recalls Industry Outline
Date:8/24/2012

LONDON, August 24, 2012 /PRNewswire/ --

Pharma IQ has just produced the Drug Recalls Industry Outline, where it analyses the challenges and implications of the late stage development failures. Pharma IQ had a quick look back over the last few years to see a timeline of drug failures and recalls at the late stages of development.

'Some of the key time saving strategies and information sources to make these decisions are trial design approaches, imaging techniques, biomarkers, strategic outsourcing and patient recruitment' says Nicola Ambler, Senior Conference Director, Pharma IQ, who is directing the upcoming Innovation in Phase 1 Clinical Development in Milan this September.

The outline analyses the drug withdrawals in the latter stages. In August 2012, Pfizer and J&J announced they were going to stop the development of the Alzheimer's drug, Bapineuzumab.  In March 2012 AstraZeneca and Targacept announced that their partnered depression drug - TC-5214 - failed at Phase III. The last two of four late-stage studies failed to meet their primary endpoints, eliminating plans for a comeback after the first two Phase III studies also ended in failure. In March 2011 Sanofi-Aventis' lung cancer drug aflibercept failed to meet its primary endpoint in a phase III trial.

The Drug Recalls Industry Outline can be accessed at http://www.phase1clinicaldevelopment.com/news

The Industry Outline was created as a part of the pre-conference preparation for the 3th Innovation in Phase I Clinical Development Forum taking place 17-19 September, 2012 in Milan. The agenda and final speaker line-up feature JW McBlane, Pharmaceutical Assessor, MHRA that will lead the session Early Clinical Studies - A Regulator's Expectations for Complex Protocols and Complex Productsand  Corina Dota, ECG Centre Director, Co-chair Cardiac QT/Arrhythmia Safety Knowledge Group from AstraZeneca presenting the case study Designing and Integrating a Robust Cardiac Safety Strategy.

Other important topics that will be discussed at the event include:

  • Biomarker development and early strategies for patients selection (case study from Roche);
  • Overcoming the internal and external challenges of developing the right biomarker at the right time (open discussion with Lundbeck);
  • Potential impact of ICH guidelines (M3, S9 and S6) on the scientific based non clinical assessment to achieve faster regulatory decisions on anticancer Phase One Clinical Trials (Italian Health Ministry)

To access the full Overview or to find out more about Phase I Clinical Development Forum 2012 please visit http://www.phase1clinicaldevelopment.com/news, email  enquire@iqpc.co.uk or call +44(0)2073689421.

Press are invited to attend this important industry forum, if you would like to a complimentary press pass please email Joanna Checinska (joanna.checinska@iqpc.co.uk)

Media contact: Joanna, +44(0)20-7368-9421, joanna.checinska@iqpc.co.uk  - Please contact for more information or images.


'/>"/>
SOURCE Pharma IQ
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):